Visual Fields Flashcards
The entire area that can be seen when the eye is directed forward, including that which is seen with peripheral vision.
Or
The entire expanse of space visible at a given instant without moving the eyes.
Visual Field
Visual Acuity
The ability to resolve something
Visual Field Tests that are used:
- Conformation
- Tangent screen
- Amsler Grid (wavy line?)
- Automated Perimetry
Visual Field Test
A test that measures the extend and distribution of the field of vision
What are the diseases that can adversely affect the visual field?
- glaucoma
- strokes (CVA)
- tumor
What medications can affect the visual field?
Hydroxychloroquine (Plaquenil) toxicity
Why do we do VF testing?
- Many diseases can affect VF
- Medications can affect VF
- Occupational safety standards
- Determination of functional loss
Give examples of occupational safety standards that are determined by VF’s
- Driver’s License qualification
- Pilots (private, commercial, military)
Give reasonings for why we do vision field testing for the determination of functional loss:
- benefits for loss of VA
- insurance reimbursements (cosmetic vs. medically necessary)
Name the different levels of Visual Field Testing
- Visual Field Screening
- Qualitative or Diagnostic Field Testing
- Quantitative Visual Field Testing
Describe VF screening
- generally done when VF loss is unlikely but possible
- should be quick, easy and capable of eliciting a wide variety of defects
Describe Qualitative or Diagnostic Field Testing
Designed to determine the characteristics of a VF defect (location, borders, size, shape, etc)
Examples: special DL testing, ptosis functional loss assessment, etc
Describe Quantitative Visual Field Testing:
-Most sophisticated Fully quantifies a known or suspended defect, so future changes detectable Requires automated (full threshold) perimetry
Incidence of VF loss is about ____
3-5%
over the age 65: 10-15%
One study (n=1500) found ___ of those appearing for first optometric eye exam had VF defects and in half the cause was sight- or life-threatening
4.4% (1 in 20-25 people)